Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Halimi, JM; Sarafidis, P; Azizi, M; Bilo, G; Burkard, T; Bursztyn, M; Camafort, M; Chapman, N; Cottone, S; de, Backer, T; Deinum, J; Delmotte, P; Dorobantu, M; Doumas, M; Dusing, R; Duly-Bouhanick, B; Fauvel, JP; Fesler, P; Gaciong, Z; Gkaliagkousi, E; Gordin, D; Grassi, G; Grassos, C; Guerrot, D; Huart, J; Izzo, R; Águila, FJ; Járai, Z; Kahan, T; Kantola, I; Kociánová, E; Limbourg, FP; Lopez-Sublet, M; Mallamaci, F; Manolis, A; Marketou, M; Mayer, G; Mazza, A; MacIntyre, IM; Mourad, JJ; Muiesan, ML; Nasr, E; Nilsson, P; Oliveras, A; Ormezzano, O; Paixão-Dias, V; Papadakis, I; Papadopoulos, D; Perl, S; Polónia, J; Pontremoli, R; Pucci, G; Robles, NR; Rubin, S; Ruilope, LM; Rump, LC; Saeed, S; Sanidas, E; Sarzani, R; Schmieder, R; Silhol, F; Sokolovic, S; Solbu, M; Soucek, M; Stergiou, G; Sudano, I; Tabbalat, R; Tengiz, I; Triantafyllidi, H; Tsioufis, K; Václavík, J; van, der, Giet, M; Van, der, Niepen, P; Veglio, F; Venzin, RM; Viigimaa, M; Weber, T; Widimsky, J; Wuerzner, G; Zelveian, P; Zebekakis, P; Lueders, S; Persu, A; Kreutz, R; Vogt, L, , European, Society, of, Hypertension, Working, Group, on, Hypertension, the, Kidney.
Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.
J Hypertens. 2024; Doi: 10.1097/HJH.0000000000003756
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Perl Sabine
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVE: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear. METHODS: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality. RESULTS: Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 15-50%) had preexisting CKD, with 10% of them (5-30%) previously referred to a nephrologist, while 30% (15-40%) had resistant hypertension. The reported rate of previous recent (<6 months) estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) testing were 80% (50-95%) and 30% (15-50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70-90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20-40%] vs. 15% [10-25], P = 0.003), GLP1-RA (10% [10-20%] vs. 5% [5-10%], P = 0.003) and mineralocorticoid receptor antagonists (20% [10-30%] vs. 15% [10-20%], P = 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries. CONCLUSIONS: Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD.
Find related publications in this database (Keywords): albuminuria; chronic kidney disease; glomerular filtration rate; hypertension; management; screening